Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is poised for continued growth in the immuno-oncology, autoimmune disorders, and infectious diseases space with its proprietary technology platforms, robust pivotal trial data for its lead product Papzimeos, and market exclusivity through 2032. The recent increase in peak penetration assumption to 10% and label expansion opportunities, along with the strong launch trajectory and access to permanent J-code, are projected to drive increased revenue and potentially accelerate the company's timeline for cash flow breakeven. While there are inherent risks in the biopharmaceutical industry, Precigen has a strong commitment to maintaining a presence at key medical meetings and driving awareness and education for its product, positioning itself for long-term success.

Bears say

Precigen is facing challenges with converting patients into actual treatment, as only 25% of the enrolled 400 patients come from the community setting, and there is no disclosure on the conversion rate of hub-to-treatment. Additionally, larger institutions operate their own hub systems, creating competition for Precigen's patient hub. The company's commercial infrastructure may also take longer to ramp up, and with a J-code unlock in 2026, it may take multiple quarters for revenue to compound and achieve cash flow breakeven. As a result, there may be limited potential for stock growth in the near future.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.